← Issue №14/ week of Oct 4, 2026/Hepatology

E3 Ubiquitin Ligases in MASH-Associated Liver Fibrosis: Mechanisms and Therapeutic Opportunities.

From GI Signals issue №14: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology review · Oct 1, 2026 · Liver International · IF 6.7

E3 Ubiquitin Ligases in MASH-Associated Liver Fibrosis: Mechanisms and Therapeutic Opportunities.

Basic sciencebasic sciencetranslationalbiomarker
Clinical takeawayNo clinical action yet: a mechanistic review of E3 ubiquitin ligases in liver fibrosis, with potential therapeutic strategies still in preclinical stages.
What it foundE3 ubiquitin ligases regulate fibrosis progression and resolution in MASH through cell type-specific mechanisms.
ContextThis review synthesizes emerging evidence on the role of E3 ubiquitin ligases in MASH-related fibrosis, highlighting their dual pro-fibrotic and anti-fibrotic effects depending on cell type and disease stage. It builds on prior understanding of fibrosis mechanisms but does not yet translate to clinical practice.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Oh AR … Kim K · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №14 Every paper GI Signals surfaces gets a page like this one. All issues